IL134056A0 - Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections - Google Patents

Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections

Info

Publication number
IL134056A0
IL134056A0 IL13405698A IL13405698A IL134056A0 IL 134056 A0 IL134056 A0 IL 134056A0 IL 13405698 A IL13405698 A IL 13405698A IL 13405698 A IL13405698 A IL 13405698A IL 134056 A0 IL134056 A0 IL 134056A0
Authority
IL
Israel
Prior art keywords
antibiotic
treatment
combination
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL13405698A
Other languages
English (en)
Original Assignee
Ambi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambi Inc filed Critical Ambi Inc
Publication of IL134056A0 publication Critical patent/IL134056A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13405698A 1997-07-23 1998-07-21 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections IL134056A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5347097P 1997-07-23 1997-07-23
PCT/US1998/015257 WO1999004809A1 (en) 1997-07-23 1998-07-21 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections

Publications (1)

Publication Number Publication Date
IL134056A0 true IL134056A0 (en) 2001-04-30

Family

ID=21984478

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13405698A IL134056A0 (en) 1997-07-23 1998-07-21 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections

Country Status (20)

Country Link
US (1) US20020006406A1 (xx)
EP (1) EP1001804B1 (xx)
JP (1) JP2001510805A (xx)
KR (1) KR20010022237A (xx)
CN (1) CN1269727A (xx)
AT (1) ATE316794T1 (xx)
AU (1) AU754806B2 (xx)
BR (1) BR9811535A (xx)
CA (1) CA2297083C (xx)
DE (1) DE69833377T2 (xx)
HU (1) HUP0002662A3 (xx)
IL (1) IL134056A0 (xx)
NO (1) NO320884B1 (xx)
NZ (1) NZ502359A (xx)
PL (1) PL338178A1 (xx)
RU (1) RU2234940C2 (xx)
SK (1) SK732000A3 (xx)
TW (1) TWI235656B (xx)
WO (1) WO1999004809A1 (xx)
ZA (1) ZA986593B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399097B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corporation Composition for treatment of a bacterial infection of the digestive tract
US6406692B1 (en) 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US6399098B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corp Composition for treating dental caries caused by streptococcus mutans
US6056954A (en) * 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US6277399B1 (en) 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
WO2001082945A2 (en) * 2000-04-28 2001-11-08 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US6395504B1 (en) 2000-09-01 2002-05-28 New Horizons Diagnostics Corp. Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants
CA2476288A1 (en) * 2002-03-26 2003-10-09 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
WO2004050846A2 (en) * 2002-12-02 2004-06-17 Biosynexus Incorporated Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
CN1744905A (zh) * 2002-12-10 2006-03-08 百敖新纳斯有限公司 局部抗感染制剂
US20100221237A1 (en) * 2003-03-26 2010-09-02 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
EP1850867A1 (en) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
EP1885403B1 (en) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
US7943128B2 (en) 2006-03-31 2011-05-17 The University Court Of The University Of St Andrews Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase
EP2037946B2 (en) * 2006-05-05 2023-11-01 Bactoclear Holdings Pte. Ltd. Phage derived antimicrobial activities
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US20090304673A1 (en) * 2008-06-10 2009-12-10 Bernd Buchberger Method of Treatment of Inflammatory Diseases
CN113717964A (zh) 2013-08-06 2021-11-30 达特茅斯学院理事会 非糖基化溶葡球菌素变体蛋白
RU2572341C2 (ru) * 2013-09-20 2016-01-10 Федеральное государственное бюджетное учреждение Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе Российской академии медицинских наук (ФГБУ "НИИНА" РАМН) АНТИБИОТИК ИНА 5812, ШТАММ-ПРОДУЦЕНТ Streptomyces roseoflavus ИНА-Ас-5812 И СПОСОБ ПОЛУЧЕНИЯ АНТИБИОТИКА
WO2019059804A1 (ru) * 2017-09-25 2019-03-28 Георгий Георгиевич ЧУМБУРИДЗЕ Термостабильная композиция, обладающая антивирусной и антибактериальной активностью и ее использование
US11565024B2 (en) 2017-11-16 2023-01-31 Georgia Tech Research Corporation Lysostaphin containing synthetic hydrogel carriers for bone repair
CN110917339B (zh) * 2019-12-27 2023-07-07 遵义医学院附属医院 一种溶葡萄球菌酶凝胶剂及其在mrsa感染创面中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
AU623864B2 (en) * 1988-08-29 1992-05-28 Applied Microbiology, Inc Method of treating mastitis and other staphylococcal infections

Also Published As

Publication number Publication date
SK732000A3 (en) 2001-03-12
TWI235656B (en) 2005-07-11
KR20010022237A (ko) 2001-03-15
WO1999004809A1 (en) 1999-02-04
AU8509598A (en) 1999-02-16
NO20000314D0 (no) 2000-01-21
EP1001804B1 (en) 2006-02-01
NZ502359A (en) 2005-02-25
HUP0002662A2 (hu) 2000-12-28
HU0002662D0 (en) 2000-08-28
JP2001510805A (ja) 2001-08-07
PL338178A1 (en) 2000-10-09
CA2297083C (en) 2007-10-30
NO320884B1 (no) 2006-02-06
NO20000314L (no) 2000-03-16
BR9811535A (pt) 2000-08-29
ZA986593B (en) 1999-02-04
EP1001804A1 (en) 2000-05-24
CA2297083A1 (en) 1999-02-04
ATE316794T1 (de) 2006-02-15
US20020006406A1 (en) 2002-01-17
DE69833377D1 (de) 2006-04-13
HUP0002662A3 (en) 2003-08-28
DE69833377T2 (de) 2006-11-16
RU2234940C2 (ru) 2004-08-27
CN1269727A (zh) 2000-10-11
AU754806B2 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
HU0002662D0 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
WO2002051424A8 (fr) Medicaments contre les defaillances articulaires
MX9701683A (es) Tratamiento terapeutico de enfermedades asociadas a clostridium difficile.
FI963232A0 (fi) Antimikrobisena aineena käytettävä hapotettu nitriitti
AU2119200A (en) Medicament
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
BG104434A (en) 2-halo-6-o-substituted ketolide derivatives
BG104340A (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
AP2002002652A0 (en) The use of azalide antibiotic composition for treating or preventing a bacterial or protozoal infection in mammals.
WO2000000214A3 (en) Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
WO2001010387A3 (en) Antiviral therapy use of P-glycoprotein modulators
MX9708611A (es) Compuestos de dialquiltiacumicina.
WO2000030435A3 (en) Foulbrood treatments
AU6633596A (en) Improved therapeutic agents
EP1114826A3 (en) Novel antibacterial and prokinetic macrolides
BG103958A (en) Pharmaceutical compositions of thioxanide and nitazoxanide
EP1671644A3 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
AUPP325398A0 (en) Improved method for eradicating h. pylori
BR9807444A (pt) Produto antimicrobial
WO2002000839A3 (en) Statement as to federally sponsored research
GEP20033144B (en) Hygromycin A Derivatives as Antibacterial Agents
WO2004000864A3 (en) 11-c-substituted ketolides
ES2104507A1 (es) Empleo de hidrolizado de gelatina para preparar una composicion farmaceutica destinada a la prevencion y tratamiento de la displasia de cadera en perros.
CA2564377A1 (en) 6-o-substituted ketolides having antibacterial activity